Table 1

Characteristics of vasculitides before and during COVID-19 19 pandemics year 2020

VasculitisSymptom duration time*
(weeks)
Disease activity/severity†
2010–201920202010–20192020
GCA4.3 (3.0–8.6)4.3 (2.0–6.9)10.0%10.0%
AAV13.0 (5.2–36.1)10.9 (5.6–21.7)16 (11–22)11 (6–21)
IgAV1.0 (0.7–2.3)1.6 (0.9–3.0)8 (3–14)8 (5–14)
  • *Median and IQR.

  • †Determined as BVAS-3 (median, IQR) in IgAV and AAV, and as percentage of patients with permanent vision defect in GCA.

  • AAV, ANCA associated vasculitis; GCA, giant cell arteritis; IgAV, IgA vasculitis.